Spirulina (Energy Bits)
What studies of Spirulina (Energy Bits) found
At a glance, by condition
Preventing long COVID: D Little or no difference
Based on the strongest evidence, the randomised trial (very low certainty), for overall symptoms.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Spirulina (Energy Bits) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Spirulina (Energy Bits) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Daily life and health overall
Overall symptoms1 study · 23 people took Spirulina (Energy Bits) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 66 people found no clear difference; a small benefit can't be ruled out.
The randomised trial66 randomised · three-month follow-up · 80 mg/kg daily
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of spirulina (Energy Bits) on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 66 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 66 randomised
- Dose
- 80 mg/kg daily
- Outcome
- frequency of symptoms after discharge in the three-month follow-up
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Side effects
Side effects studies reported2 kinds
| Side effect | Studies that reported it |
|---|---|
| Headache | 1 study |
| Nausea or stomach upset | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
80 mg at the start
- 2Top dose
Most often 80 mg (1 of 1 studies)
Doses across 1 study
80 to 80 mg.
Each study’s dose, as printed
All papers
- Therapeutic Efficacy of Spirulina Algae and N-Acetylcysteine in COVID-19 Hospitalized Patients: A Randomized Phase II Clinical Trial2024 · randomised trial · 66 randomised
Summary
The study aimed to evaluate spirulina and N-acetylcysteine in the treatment of hospitalized patients with Coronavirus Disease 2019 (COVID-19). This multicenter, randomized, single-masked, open-label phase II clinical trial enrolled 66 patients with COVID-19. Patients were randomly assigned to one group that received spirulina algae (23 people), one group that received N-acetylcysteine plus spirulina algae (21 people), or a control group (22 people) that received only the national standard treatment for COVID-19. The intervention groups were prescribed 80 mg/kg of spirulina green algae daily; the N-acetylcysteine dose and treatment duration were not reported. The study reported no significant difference between the three groups for duration of hospitalization (P = 0.874), Intensive Care Unit (ICU) admission (P = 0.320), or mortality (P = 0.320). Side effects, including headache (P = 0.022) and nausea (P = 0.039), were significantly less common in the control group. At the three-month follow-up, no statistically significant difference was observed regarding the frequency of symptoms after discharge (P = 0.420). The authors concluded that administering spirulina with or without N-acetylcysteine did not affect length of hospitalization, ICU admission, mortality, and the frequency of symptoms or long COVID. The text does not report limitations.